NATIONAL
CANCER
INSTITUTE

NCI Cancer Bulletin
A Trusted Source for Cancer Research News
January 18, 2005 • Volume 2 / Number 3 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe


Bulletin Home

Featured Article
Exploring Future Investment Strategies: NCI Advisory Board Retreat

Director's Update
Despite Challenges, A Commitment to Excellence

Spotlight
New NCI Clinical Trial Program Benefits People and Pets

Cancer Research Highlights
FDA Approves Abraxane for Breast Cancer

Androgen Deprivation Therapy Increases Fracture Risk

Deficient DNA Repair Capacity Increases Breast Cancer Risk

Diabetes and Cancer Risk Link Not Tied to Obesity

Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible

HHS News
HHS/USDA Release Updated Dietary Guidelines

Funding Opportunities

Featured Clinical Trial
Combination Chemotherapy for Adrenocortical Cancer

Notes
New Members Appointed to DCLG

NCI Scientists to Speak at Gordon Conference

NCI Launches Nanotechnology Seminar Series

CCR Grand Rounds

Guest Commentary
Make Real Resolutions: Healthy Eating and Active Living

Bulletin Archive

Page Options
Print This Page
Print This Document
View Entire Document
E-Mail This Document
View/Print PDF
Featured Article

Exploring Future Investment Strategies:
NCI Advisory Board Retreat


On Dec. 9 2004, the President signed the Omnibus Appropriations bill into law. As noted in the December 14 NCI Cancer Bulletin, the initial National Cancer Institute (NCI) appropriation increase was $141 million; however, after adjustments are made for rescissions, assessments, and mandatory increases, NCI starts with fewer dollars than in fiscal year 2004. Shortly following receipt of the FY 2005 budget, NCI's director and its senior management team reviewed all of the program needs from across NCI and established operating policies and paylines for Research Project Grants (RPGs). For this year - FY 2005 - the success rate for RPGs is expected to be 21 percent, or 1,346 competing RPGs; the R01 payline for percentiled grants is established at the 16th percentile; increases for competing renewal RPGs will range from 5 to 10 percent above current levels; and full cost-of-living adjustments will be provided for RPG noncompeting (type 5), nonmodular grants.

Last week, members of three key NCI advisory boards held a joint retreat to discuss issues facing the institute in light of diminishing resources. The meeting of the Board of Scientific Advisors (BSA), Board of Scientific Counselors (BSC), and National Cancer Advisory Board (NCAB), including the Chairs of the President's Cancer Panel and the Director's Consumer Liaison Group, served as a backdrop for what NCI Director Dr. Andrew C. von Eschenbach described as a discussion "not just about where we are, but where we want to be."

Acknowledging that essentially flat budgets are likely for the near future, Dr. von Eschenbach stressed that, nonetheless, "We are going to continue to grow, to become more innovative, more focused…and we're going to have to make tough decisions."  Read more  

Director's Update

Despite Challenges, A Commitment to Excellence

Speaking to a room of NCI researchers and investigators last week, NCI Deputy Director Dr. Alan Rabson reflected on his 50 years at the National Institutes of Health (NIH), all but the first year of which he has spent as an NCI employee. I've had the pleasure of working with this extraordinary man since my arrival at NCI, and over the past 3 years I have seen the skills, talent, and energy that have exemplified every moment of his long career. He is a role model of the true meaning of commitment and excellence, always putting NCI, its people, and its mission first.

Al launched the NCI Combined Intramural Principal Investigator retreat as he introduced Dr. Susan Gottesman, the winner of the first annual Alan Rabson Award for NCI Intramural Research. Dr. Gottesman, of the Laboratory of Molecular Biology in NCI's Center for Cancer Research (CCR), has been with NCI for 28 years and is internationally recognized as a leader in identifying small RNA and its function.  Read more  

The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI). NCI, which was established in 1937, leads the national effort to eliminate the suffering and death due to cancer. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.

For more information on cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.

NCI Cancer Bulletin staff can be reached at ncicancerbulletin@mail.nih.gov.

Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov